RespireRx Pharmaceuticals Inc (RSPID)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

126 VALLEY ROAD GLEN ROCK, NJ 07452

Cortex Pharmaceuticals' primary focus is to develop small molecule compounds that positively modulate AMPA-type glutamate receptors, a complex of proteins involved in the communication between nerve cells in the mammalian brain. These compounds, termed AMPAKINE compounds, enhance the activity of the AMPA receptor. These molecules are designed and developed as proprietary pharmaceuticals for the treatment of neurological and psychiatric diseases and disorders that are known, or thought, to involve depressed functioning of pathways in the brain that use glutamate as a neurotransmitter. Co.'s clinical compounds include CX717 and CX1739, both of which are in Phase II clinical.

Data as of 2019-12-02 13:21:06 -0500
Market Cap629.402 Thousand Shares Outstanding4.045 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-0.563
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low1.1 / 0.1556 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from RSPID instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding RSPID (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RSPID BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LIPPA ARNOLD EXEC. CHAIRMAN & CSO

  • Officer
  • Director
0 2020-09-30 1

MARGOLIS JEFF ELIOT SVP, CFO, SECRET'Y & TREASURER

  • Officer
  • Director
  • 10% Owner
106,436,565 2020-09-30 1

MACFARLANE KATIE

  • Director
0 2020-09-30 2

JONES TIMOTHY L. CEO AND PRESIDENT

  • Officer
  • Director
4,409,063 2020-09-30 2

DICKASON DAVID SVP OF PRE-CLINICAL PROD. DEV.

  • Officer
0 2020-09-30 2

PURCELL RICHARD DAVID JR. SVP - RESEARCH AND DEVELOPMENT

  • Officer
0 2020-07-31 1

SAPIRSTEIN JAMES

  • Director
0 2017-12-09 0

MANUSO JAMES S J PRESIDENT AND CEO

  • Officer
  • Director
74,252 2017-09-13 0

WEINGARTEN ROBERT N EVP & CHIEF FINANCIAL OFFICER

  • Officer
  • Director
0 2017-01-18 0

COLEMAN JAMES H SR. VP, BUSINESS DEVELOPMENT

  • Officer
0 2012-08-10 0

STOLL ROGER G PHD EXECUTIVE CHAIRMAN

  • Officer
  • Director
0 2012-08-10 0

BENEDIK JOHN F

  • Director
0 2012-08-03 0

COTMAN CARL W

  • Director
0 2012-08-03 0

ALLNUTT ROBERT

  • Director
0 2012-08-03 0

CASAMENTO CHARLES J

  • Director
0 2012-08-03 0

DRAKE PETER F

  • Director
0 2012-08-03 0

JOHNSON M ROSS

  • Director
0 2012-08-03 0

HWANG MOOGAK

  • Director
0 2012-08-03 0

SAMYANG OPTICS CO., LTD

  • 10% Owner
6,765,466 2011-10-20 0

JOHNSON STEVEN ANDREW VP, PRECLINICAL DEVELOPMENT

  • Officer
0 2009-12-31 0

MESSINGER MARIA S CHIEF FINANCIAL OFFICER

  • Officer
0 2009-08-22 0

VARNEY MARK A PRESIDENT AND CEO

  • Officer
  • Director
0 2009-08-22 0

TRAN PIERRE V CHIEF MEDICAL OFFICER

  • Officer
0 2009-08-22 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments